rs567534295
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analyses performed under logistic model, linear mixed model, and model incorporating correlations identified nine significant associations with three gynecologic diseases including four novel findings (rs79219469:C > T, LINC02183, P = 3.3 × 10<sup>-8</sup> and rs567534295:C > T, BRCA1, P = 3.1 × 10<sup>-8</sup> with OC, rs150806792:C > T, INS-IGF2, P = 4.9 × 10<sup>-8</sup> and rs140991990:A > G, SOX9, P = 3.3 × 10<sup>-8</sup> with UCC).
|
31488892 |
2020 |
rs1051740
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Overall results demonstrated that the association between <i>EPHX1</i> polymorphism rs1051740</span> and ovar</span>ian cancer risk had no statistical significance either in total analysis or in subgroup analyses by ethnicity and source of control.
|
31174441 |
2019 |
rs3020450
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the correlation between the polymorphism of estrogen receptor β gene (ESR2) rs3020450 and cancer susceptibility, and explore the epidemiological significance and the effect of ESR2 expression levels on the prognosis of ovarian cancer.
|
31200086 |
2019 |
rs876658657
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Correction: The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
|
31150525 |
2019 |
rs12373237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The CC homozygous mutation of rs12373237 was highly correlated with the onset of ovarian cancer (OR=4.333, P=0.028).
|
31402958 |
2019 |
rs137853011
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This karyotype phenotype was not observed in other tested tissues or in an ovarian cancer patient with a different homozygous missense mutation in <i>CHEK2</i> (c.1283C>T; p.Ser428Phe).
|
30858171 |
2019 |
rs200640585
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.
|
31056861 |
2019 |
rs2516839
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Taken together, our results suggest that the rs2516839 polymorphism in USF1 gene may associate with the efficacy and safety of paclitaxel-based chemotherapy and prognosis in the treatment of OC.
|
29322800 |
2019 |
rs2699887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interaction between PIK3CA rs2699887 SNP and age, number of liveborn, tobacco, alcohol, a family history of ovarian cancer and other factors are associated with ovarian cancer risk.
|
31288947 |
2019 |
rs3212986
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 rs3212986 (C/A) polymorphisms posed an increased risk for breast and ovarian cancer as whole (A vs C: OR = 1.12, 95% CI = 1.01-1.25; AA + CA vs CC: OR = 1.11, 95% CI = 1.02-1.22), and presented especially higher risk for ovarian cancer (A vs C: OR = 1.31, 95% CI = 1.05-1.63; AA vs CA + CC: OR = 1.66, 95% CI = 1.12-2.47; AA vs CC: OR = 1.72, 95% CI = 1.12-2.64).
|
31081240 |
2019 |
rs3737787
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study was supposed to investigate the correlation between the functional single nucleotide polymorphisms (SNPs) (rs2516839 and rs3737787) in USF1 gene and the efficacy and safety of paclitaxel-based chemotherapy and prognosis in the treatment of ovarian cancer (OC).
|
29322800 |
2019 |
rs3976507
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interaction between PIK3CA rs3976507 and rs6443626 loci, and factors such as BMI, number of liveborn, tobacco, alcohol, and family history of ovarian cancer are associated with ovarian cancer risk.
|
31288947 |
2019 |
rs587778617
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.
|
31056861 |
2019 |
rs6443626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interaction between PIK3CA rs3976507 and rs6443626 loci, and factors such as BMI, number of liveborn, tobacco, alcohol, and family history of ovarian cancer are associated with ovarian cancer risk.
|
31288947 |
2019 |
rs79722116
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, two non-synonymous SNPs rs201407189 (c.973G>A, p.A325T) and rs1800367 (c.1345G>A, p.V449M), and two synonymous SNPs rs55719336 (c.816C>T, p.I272I) and rs79722116 (c.1407G>A, p.T469T) were identified in FBOC patients.
|
30967997 |
2019 |
rs80356897
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, two non-synonymous SNPs rs201407189 (c.973G>A, p.A325T) and rs1800367 (c.1345G>A, p.V449M), and two synonymous SNPs rs55719336 (c.816C>T, p.I272I) and rs79722116 (c.1407G>A, p.T469T) were identified in FBOC patients.
|
30967997 |
2019 |
rs80357268
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRCA1, p.(Val1833Met) is possibly a disease-associated variant, supported by a likelihood ratio of 1.88, while a correlation to ovarian cancer is suspected.
|
31447071 |
2019 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The homozygote model with the rs2228570 (FokI) polymorphism model appeared to detect the risk of OC in all cases, whereas the heterozygote model with the rs1544410 (BsmI) polymorphism seemed to detect the risk of OC in Caucasian patients.
|
30059751 |
2018 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The rs2228570 polymorphism increased the risk of ovarian cancer in Caucasian populations in a dominant genetic model.
|
29239065 |
2018 |
rs1271572
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The recessive model of ESR2 rs1271572 and the dominant model of ESR2 rs3020450 might be susceptible factors for ovarian cancer.
|
29535531 |
2018 |
rs1695
|
|
|
0.030 |
GeneticVariation |
BEFREE |
<i>GSTP1</i> rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.
|
30038720 |
2018 |
rs1799950
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Further characterisation of rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
|
29298688 |
2018 |
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This study indicated that XRCC1 Arg194Trp, Arg280His, and Arg399Gln did not affect OS after platinum-based chemotherapy in OC patients.
|
30407287 |
2018 |
rs1136201
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Furthermore, no significant association between allelic, dominant, codominant and recessive models of HER2 rs1801200 (V655I) and ovarian cancer was found (<i>p</i> > 0.05).
|
29535531 |
2018 |
rs11571833
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer.
|
29767749 |
2018 |